Gross margins have experienced structural compression, falling from a peak of 77.6% in 2023Q4 to 50.4% in 2026Q1 due to the rising costs associated with discovery-related activities.
| Sales/Revenue | 254.91M | 255.87M | 207.54M | 216.67M | 180.96M | 137.93M | 108.09M | 85.54M | 66.64M | 55.69M |
| Revenue Growth % | 10.59% | 23.29% | -4.21% | 19.73% | 31.19% | 27.6% | 26.36% | 28.37% | 19.65% | - |
| Cost of Goods Sold | 113.87M | 113.25M | 75.46M | 75.97M | 79.93M | 72.31M | 44.62M | 36.45M | 23.7M | 15.89M |
| COGS % of Revenue | - | 44.26% | 36.36% | 35.07% | 44.17% | 52.43% | 41.28% | 42.61% | 35.57% | 28.54% |
| Gross Profit | 141.04M | 142.61M | 132.08M | 140.69M | 101.02M | 65.62M | 63.47M | 49.09M | 42.94M | 39.8M |
| Gross Margin % | 55.33% | 55.74% | 63.64% | 64.94% | 55.83% | 47.57% | 58.72% | 57.39% | 64.43% | 71.46% |
| Gross Profit Growth % | - | 7.97% | -6.12% | 39.27% | 53.95% | 3.38% | 29.29% | 14.34% | 7.88% | - |
| Operating Expenses | 305.84M | 309.51M | 341.38M | 318.14M | 247.84M | 177.06M | 124.39M | 87.81M | 70.91M | 58.82M |
| OpEx % of Revenue | - | 120.96% | 164.49% | 146.83% | 136.96% | 128.37% | 115.07% | 102.65% | 106.4% | 105.62% |
| Selling, General & Admin | 134.72M | 136.37M | 139.59M | 136.37M | 121.47M | 86.16M | 59.69M | 48.4M | 36.38M | 31.15M |
| SG&A % of Revenue | - | 53.3% | 67.26% | 62.94% | 67.13% | 62.47% | 55.22% | 56.58% | 54.6% | 55.94% |
| Research & Development | 171.12M | 173.14M | 201.78M | 181.77M | 126.37M | 90.9M | 64.69M | 39.4M | 34.52M | 27.67M |
| R&D % of Revenue | - | 67.67% | 97.23% | 83.89% | 69.84% | 65.91% | 59.85% | 46.06% | 51.81% | 49.68% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -164.8M | -166.9M | -209.3M | -177.45M | -146.82M | -111.44M | -60.92M | -38.72M | -27.97M | -19.02M |
| Operating Margin % | -64.65% | -65.23% | -100.85% | -81.9% | -81.13% | -80.8% | -56.35% | -45.26% | -41.97% | -34.15% |
| Operating Income Growth % | - | 20.26% | -17.95% | -20.86% | -31.74% | -82.95% | -57.34% | -38.42% | -47.04% | - |
| EBITDA | -158.69M | -160.87M | -203.14M | -171.9M | -142.47M | -108.6M | -57.26M | -35.08M | -25.07M | -17.34M |
| EBITDA Margin % | -62.25% | -62.87% | -97.88% | -79.34% | -78.73% | -78.73% | -52.97% | -41% | -37.63% | -31.13% |
| EBITDA Growth % | 14.89% | 20.81% | -18.17% | -20.65% | -31.2% | -89.66% | -63.24% | -39.88% | -44.64% | - |
| D&A (Non-Cash Add-back) | 6.12M | 6.02M | 6.16M | 5.55M | 4.34M | 2.85M | 3.66M | 3.64M | 2.89M | 1.69M |
| EBIT | -91.34M | -102.33M | -209.3M | -177.45M | -146.82M | -111.44M | -60.92M | -38.72M | -27.97M | -19.02M |
| Net Interest Income | 0 | 0 | 0 | 0 | 3.95M | 1.06M | 2.25M | 1.88M | 433K | 359K |
| Interest Income | 0 | 0 | 0 | 0 | 3.95M | 1.06M | 2.25M | 1.88M | 433K | 359K |
| Interest Expense | 0 | 0 | 0 | 0 | 3K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 62.64M | 64.57M | 23.59M | 220.37M | -2.31M | 10.63M | 34.62M | 12.74M | -379K | 1.96M |
| Pretax Income | -102.16M | -102.33M | -185.71M | 42.92M | -149.12M | -100.81M | -26.29M | -25.97M | -28.35M | -17.06M |
| Pretax Margin % | -40.08% | -39.99% | -89.48% | 19.81% | -82.41% | -73.09% | -24.32% | -30.36% | -42.54% | -30.63% |
| Income Tax | 1.32M | 939K | 1.41M | 2.2M | 63K | 411K | 345K | -291K | 77K | 332K |
| Effective Tax Rate % | -1.29% | -0.92% | -0.76% | 5.12% | -0.04% | -0.41% | -1.31% | 1.12% | -0.27% | -1.95% |
| Net Income | -103.48M | -103.27M | -187.12M | 40.72M | -149.19M | -100.39M | -24.46M | -24.57M | -28.43M | -17.39M |
| Net Margin % | -40.6% | -40.36% | -90.16% | 18.79% | -82.44% | -72.78% | -22.63% | -28.72% | -42.66% | -31.23% |
| Net Income Growth % | 46.16% | 44.81% | -559.54% | 127.29% | -48.6% | -310.39% | 0.44% | 13.56% | -63.44% | - |
| Net Income (Continuing) | -103.48M | -103.27M | -187.12M | 40.72M | -149.19M | -101.22M | -26.64M | -25.68M | -28.43M | -17.39M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 11K | 14K | 4K | 41K | 0 | 0 |
| EPS (Diluted) | -1.40 | -1.41 | -2.57 | 0.54 | -2.10 | -1.43 | -0.44 | -0.41 | -0.59 | -3.07 |
| EPS Growth % | 46.39% | 45.14% | -575.93% | 125.71% | -46.85% | -225% | -7.32% | 30.51% | 80.78% | - |
| EPS (Basic) | - | -1.41 | -2.57 | 0.57 | -2.10 | -1.43 | -0.44 | -0.41 | -0.59 | -3.07 |
| Diluted Shares Outstanding | 73.99M | 73.44M | 72.67M | 74.99M | 71.17M | 70.59M | 60.02M | 63.27M | 48.47M | 5.67M |
| Basic Shares Outstanding | 73.99M | 73.44M | 72.67M | 71.78M | 71.17M | 70.59M | 60.02M | 63.27M | 48.47M | 5.67M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Clinical Pipeline Execution Risk
As reported in financial statements, Schrödinger's revenue growth remains highly inconsistent, oscillating between a 62.7% surge in 2025Q1 and a 1.6% contraction in 2026Q1, reflecting the inherent unpredictability of milestone-driven drug discovery income compared to the more stable, albeit slower-growing, core software licensing business.
The revenue profile suggests a business model struggling to reconcile recurring software demand with the episodic nature of collaboration milestones. Investors should monitor whether the company can decouple its growth trajectory from these lumpy transactional events to demonstrate sustainable, organic expansion.
Based on reported figures, gross margins have fluctuated significantly, peaking at 77.6% in 2023Q4 before compressing to 50.4% in 2026Q1, which suggests that the increasing weight of discovery-related costs is diluting the high-margin profile typically associated with the company's proprietary software platform.
This margin volatility appears to be a direct consequence of shifting resources toward internal drug development, which carries higher direct costs than software delivery. The inability to maintain consistent gross margins warrants further investigation into the scalability of the discovery segment's cost structure.
According to recent SEC filings, Schrödinger's R&D expenditure has remained stubbornly high, consistently exceeding $40 million per quarter, which effectively prevents the company from achieving operating leverage despite the potential for software-driven scalability within its core computational molecular modeling business model.
The persistent R&D spend indicates a management strategy prioritizing long-term pipeline development over near-term operating profitability. This heavy investment cycle may indicate that the company is still in a capital-intensive phase, necessitating continued scrutiny of the return on invested capital for these internal programs.
As indicated by the income statement data, the pivot toward wholly-owned clinical assets like SGR-1505 introduces significant financial risk, as the company's operating losses remain substantial, with net income reaching -$60.0 million in 2026Q1, potentially forcing a reliance on external capital if milestones fail to materialize.
Short-sellers may focus on the potential for 'diworsification' as the company moves away from its high-margin software roots into the capital-hungry world of clinical trials. The current burn rate suggests that the company's financial stability is increasingly tied to the success of its internal pipeline rather than its established software moat.
Quick answers to the most common questions about buying SDGR stock.
For fiscal year 2025, Schrödinger, Inc. (SDGR) reported total revenue of $255.9M. This represents a 359.4% increase compared to $55.7M in 2017.
Schrödinger, Inc. (SDGR) reported a net loss of $103.3M for the fiscal year ending 2025.
Schrödinger, Inc. (SDGR) reported an operating income of $-166.9M, resulting in an operating profit margin of -65.2%. This margin reflects the operational efficiency of the business before interest and taxes.
Schrödinger, Inc. (SDGR) generated $142.6M in gross profit for the year, representing a gross profit margin of 55.7%. This demonstrates the company's core pricing power and production efficiency.